Cytokinetics Presents New Aficamten Data From ACACIA-HCM And FOREST-HCM At HCMS Scientific Sessions 2026
Benzinga Newsdesk 4 hours ago
News
New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for AficamtenSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that
New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for Aficamten
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that new data related to aficamten were presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions held in collaboration with the American Heart Association Scientific Sessions 2026 in Chicago, IL including two late-breaking oral abstracts with additional data from ACACIA-HCM, and one poster presentation with new data from FOREST-HCM.